Story at-a-glance
- Johnson & Johnson has agreed to pay more than $1 billion in a civil settlement involving fraudulent marketing of their antipsychotic drug Risperdal
- The drug was heavily promoted for unproven off-label uses for more than a decade, even after the U.S. Food and Drug Administration issued warnings against the misleading claims
- Research has shown that up to two-thirds of prescriptions for Risperdal were for unapproved uses that had little or no scientific support. One commonly promoted use was for dementia, but elderly dementia patients who were prescribed Risperdal for off-label uses were found to increase their chances of death by 54 percent within the first 12 weeks of taking it!
- Drug companies, including not only Johnson & Johnson but many others, continue to be among the top corporate criminals on the planet… which makes trusting the products they produce a risky proposition, at best
No comments:
Post a Comment